Literature DB >> 25865153

The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting.

S P Menting1, J M P A van den Reek2, E M Baerveldt3, E M G J de Jong2, E P Prens3, L L A Lecluse4, G J Wolbink5, D Van der Kleij5,6, Ph I Spuls4, T Rispens5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25865153     DOI： 10.1111/bjd.13834

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  11 in total

1.  Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease.

Authors:  Claire Painchart; Séverine Brabant; Nicolas Duveau; Maria Nachury; Pierre Desreumaux; Julien Branche; Romain Gérard; Clémentine Lauriot Dit Prevost; Pauline Wils; Thomas Lambin; Médina Boualit; Myriam Labalette; Benjamin Pariente
Journal:  Dig Dis Sci       Date:  2019-10-10       Impact factor: 3.199

Review 2.  How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease.

Authors:  Parambir S Dulai; Siddharth Singh; Niels V Casteele; Brigid S Boland; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

3.  Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial.

Authors:  C I Busard; S P Menting; J S van Bezooijen; J M van den Reek; B A Hutten; E P Prens; E M de Jong; M B van Doorn; P I Spuls
Journal:  Trials       Date:  2017-02-02       Impact factor: 2.279

Review 4.  Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.

Authors:  Erwin Dreesen; Peter Bossuyt; Denis Mulleman; Ann Gils; Dora Pascual-Salcedo
Journal:  Clin Pharmacol       Date:  2017-10-03

5.  Clinical Consequences of Antibody Formation, Serum Concentrations, and HLA-Cw6 Status in Psoriasis Patients on Ustekinumab.

Authors:  Eline De Keyser; Celine I Busard; Sven Lanssens; Lieve Meuleman; Barbara A Hutten; Antonio Costanzo; Juul M van den Reek; Jeffrey Zweegers; Jo Lambert; Phyllis I Spuls
Journal:  Ther Drug Monit       Date:  2019-10       Impact factor: 3.681

6.  Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study.

Authors:  Shan Pan; Teresa Tsakok; Nick Dand; Dagan O Lonsdale; Floris C Loeff; Karien Bloem; Annick de Vries; David Baudry; Michael Duckworth; Satveer Mahil; Angela Pushpa-Rajah; Alice Russell; Ali Alsharqi; Gabrielle Becher; Ruth Murphy; Shyamal Wahie; Andrew Wright; Christopher E M Griffiths; Nick J Reynolds; Jonathan Barker; Richard B Warren; A David Burden; Theo Rispens; Joseph F Standing; Catherine H Smith
Journal:  Clin Transl Sci       Date:  2020-01-29       Impact factor: 4.689

7.  Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis.

Authors:  N Van den Berghe; E De Keyser; R Soenen; L Meuleman; S Lanssens; A Gils; J Lambert
Journal:  Br J Dermatol       Date:  2019-07-24       Impact factor: 9.302

8.  Fire needle acupuncture or moxibustion for chronic plaque psoriasis: study protocol for a randomized controlled trial.

Authors:  Zhaoxia Chen; Dongmei Zhou; Yan Wang; Haibing Lan; Xingwu Duan; Bohua Li; Jingxia Zhao; Wei Li; Zhengrong Liu; Tingting Di; Xinwei Guo; Jinchao Zhang; Bo Li; Shuo Feng; Ping Li
Journal:  Trials       Date:  2019-12-04       Impact factor: 2.279

9.  The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.

Authors:  A R J V Vossen; C B Ardon; H H van der Zee; E Lubberts; E P Prens
Journal:  Br J Dermatol       Date:  2019-04-12       Impact factor: 9.302

Review 10.  Advances in the development of new biologics in inflammatory bowel disease.

Authors:  Bella Ungar; Uri Kopylov
Journal:  Ann Gastroenterol       Date:  2016-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.